Agios Pharmaceuticals has been granted a patent for compounds of Formula I or its pharmaceutically acceptable salt, useful in stabilizing mutant PAH protein or reducing blood phenylalanine levels in phenylketonuria patients. The compounds target specific mutations like R408W, R261Q, and Y414C. GlobalData’s report on Agios Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Agios Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Agios Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Agios Pharmaceuticals's grant share as of February 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.

The granted patent (Publication Number: US11919915B2) discloses a compound of Formula I-B-1, along with its various derivatives and pharmaceutically acceptable salts. The compound, when R5 is H, R1 is unspecified, and Ra is selected from a list of substituents including F, Br, Cl, methyl, ethyl, and others. Additionally, R6 can be pyridinyl, pyrazolyl, pyrazinyl, and other groups, optionally substituted with halo, alkyl, alkoxy, or cycloalkylsulfonyl.

Furthermore, the patent claims the compound to be an S-enantiomer and provides a list of specific compounds falling under this category. These compounds are part of a pharmaceutical composition along with a pharmaceutically acceptable excipient. The patent aims to protect the unique chemical structure and potential therapeutic applications of the disclosed compound and its derivatives.

To know more about GlobalData’s detailed insights on Agios Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies